「ロシア直接投資基金」の写真・グラフィックス・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 提供元
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 0
- 期間を指定 5
- 日付指定なし 5
- 種類
- 写真 5
- グラフィックス 0
- 映像 0
- 向き
- 縦 0
- 横 5
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 5
- モノクロ 0
- 古い順
- 1
- 古い順
2021年04月19日Russian Sputnik V COVID-19 VaccineApril 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021042009484
2021年04月19日Russian Sputnik V COVID-19 VaccineApril 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021042009342
2021年04月19日Russian Sputnik V COVID-19 VaccineApril 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021042009523
2021年04月19日Russian Sputnik V COVID-19 VaccineApril 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021042005279
2021年04月19日Russian Sputnik V COVID-19 VaccineApril 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021042009524
- 1
